secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001099800-24-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q1 sales $1.6B (+10%), TMTT +75%; raises FY sales guidance to high end 8-10%
--------------------------------------------------------------------------------

- Q1 sales $1.6B, up 10% reported and constant currency; GAAP EPS $0.58, adjusted EPS $0.66.
- TAVR sales $1.0B (+6% reported, +8% constant currency adjusted for billing days).
- TMTT sales $73M (+75%); EVOQUE received FDA approval for tricuspid regurgitation in Feb.
- Full-year 2024 sales guidance raised to high end of 8-10% range; TMTT guidance raised to $320-340M.
- Critical Care spin-off on track; full-year adjusted EPS guidance maintained at $2.70-$2.80.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000037/0001099800-24-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000037/ew-20240425.htm
  HTML page:      https://secwatch.observer/filing/0001099800-24-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer